ArticleJournal of inflammation research2025
Anti-Psoriatic Efficacies of Psorogrit and Divya-Taila, in Murine Models of Imiquimod and TPA-Induced Psoriasis-Like Inflammation are Driven by Modulation in IL-17RA/IL-23 and IL-8/TNF-α Signaling Axes.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Psoriasis is a chronic inflammatory skin disease that occurs among all age groups, irrespective of gender, and consequently it negatively impacts patient's quality of life. Medicines of herbo-mineral origin are being increasingly used for the mitigation of psoriasis, due to the side effects associated with the available treatment options. Present study characterizes the pharmacological efficacy of Psorogrit (PSO) and Divya-Taila (DT) using in vitro and in vivo assays. Methods: Human keratinocyte (HaCaT) cells stimulated with TNF-α or Imiquimod (IMQ) were used to generate the in vitro models of psoriasis. PSO was further evaluated for modulation of mRNA expression, cytokine levels and NF-κB reporter activity. The in vivo anti-psoriatic activity of the orally given PSO and topically applied DT was assessed in mouse models of IMQ-induced psoriasis-like skin lesions and 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ear edema. The animals were randomly allocated to the Normal control, Disease control, Clobetasol, PSO and DT groups. Analysis of ear thickness, ear punch weight, spleen weight, histopathology by hematoxylin and eosin (H&E), and Results: Cytosafe concentrations of PSO significantly attenuated IL-8 release as well as mRNA expressions of Conclusion: The combinatorial use of Psorogrit and Divya-Taila has the potential to ameliorate clinical and pathological manifestations of psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.